Role of sirtuin-1 in diabetic nephropathy

Wanning Wang \(^1,2\) · Weixia Sun \(^1\) · Yanli Cheng \(^1\) · Zhonggao Xu \(^1\) · Lu Cai \(^2,3\)

Received: 5 September 2018 / Revised: 29 December 2018 / Accepted: 9 January 2019 / Published online: 1 February 2019 © The Author(s) 2019

Abstract

Diabetic nephropathy (DN) is a research priority for scientists around the world because of its high prevalence and poor prognosis. Although several mechanisms have been shown to be involved in its pathogenesis and many useful drugs have been developed, the management of DN remains challenging. Increasing amounts of evidence show that silent information regulator 2 homolog 1 (sirtuin-1), a nicotinamide adenine dinucleotide (NAD+)–dependent protein deacetylase, plays a crucial role in the pathogenesis and development of DN. Clinical data show that gene polymorphisms of sirtuin-1 affect patient vulnerability to DN. In addition, upregulation of sirtuin-1 attenuates DN in various experimental models of diabetes and in renal cells, including podocytes, mesangial cells, and renal proximal tubular cells, incubated with high concentrations of glucose or advanced glycation end products. Mechanistically, sirtuin-1 has its renoprotective effects by modulating metabolic homeostasis and autophagy, resisting apoptosis and oxidative stress, and inhibiting inflammation through deacetylation of histones and the transcription factors p53, forkhead box group O, nuclear factor-κB, hypoxia-inducible factor-1α, and others. Furthermore, some microRNAs have been implicated in the progression of DN because they target sirtuin-1 mRNA. Several synthetic drugs and natural compounds have been identified that upregulate the expression and activity of sirtuin-1, which protects against DN. The present review will summarize advances in knowledge regarding the role of sirtuin-1 in the pathogenesis of DN. The available evidence implies that sirtuin-1 has great potential as a clinical target for the prevention and treatment of diabetes.

Keywords Sirtuin-1 · Deacetylase · Diabetic nephropathy · Signaling pathway · Pathogenesis

Background

Diabetic nephropathy (DN), also referred to as diabetic kidney disease, occurs in 20–40% of all diabetic patients, and therefore affects hundreds of millions of people worldwide [1]. The early stages of DN are characterized by microalbuminuria, which is usually ignored. However, when this albuminuria becomes severe, it is progressive and irreversible, ultimately being associated with renal dysfunction and a high risk of cardiovascular death. Although a lot of progress has been made in the understanding of the mechanisms and appropriate treatment of DN, it remains a substantial clinical problem.

Acetylation and deacetylation regulate cell proliferation, apoptosis, autophagy, energy homeostasis, inflammation, and oxidative stress (OS). Acetylation of histone promotes transcription by opening chromatin binding sites, and acetylation of transcription factors and transcriptional coregulatory proteins regulate their transcriptional activity by modulating their subcellular localization, DNA-binding affinity, and degradation [2]. Deacetylases counteract these effects by removing acetyl groups [3]. Sirtuins are nicotinamide adenine
Pathogenic features and molecular mechanisms of diabetic nephropathy

DN is a chronic complication of diabetes, and its clinical and pathological characteristics require many years to develop in humans. The natural history of DN caused by type 1 diabetes mellitus (T1DM; the consequence of the autoimmune destruction of pancreatic islet beta-cells) is further divided into five stages: normoalbuminuria with hyperfiltration, microalbuminuria, macroalbuminuria, decline of the glomerular filtration rate (GFR), and the dialysis-dependent stage [9, 10]. DN caused by type 2 diabetes mellitus (T2DM; the consequence of insulin resistance (IR) and the failure of beta-cell compensation) seems to be more complex and progresses more rapidly due to the presence of IR and other disturbances, such as hypertension. The histological alterations characterizing DN can be identified in glomeruli, tubules, the interstitium, and vessels.

The glomerular defects are the most important lesions, involving a reduction in podocyte number and foot process effacement, glomerular basement membrane thickening, mesangial expansion, nodular sclerosis, and global glomerulosclerosis [11]. The reduction in podocyte number is caused by apoptosis and detachment; podocytes detachment and foot process effacement are due to cytoskeletal changes and podocyte de-differentiation. Because they are a critical component of the mechanism of glomerular filtration, the loss of and phenotypic alterations in podocytes are the principal cause of albuminuria in DN. The mesangial expansion and glomerulosclerosis result from mesangial cell proliferation, hypertrophy, phenotypic changes, and subsequently excessive mesangial matrix accumulation, which ultimately result in lower GFR. Tubular epithelial cells in diabetic kidneys can undergo hypertrophy, apoptosis, and/or transformation into mesenchymal cells. Simultaneously, the interstitium becomes infiltrated with pro-inflammatory cells and fibroblasts. The progression of tubulointerstitial fibrosis and glomerulosclerosis causes a deterioration in renal dysfunction. Furthermore, diabetes induces arteriolar hyalinosis. Thus, during the progression of DN, nearly all the cell types in the kidney demonstrate abnormalities, including proliferation, hypertrophy, de-differentiation, and apoptosis.

Evidence for the role of sirtuin-1 in humans and animal models of diabetic nephropathy

There is emerging clinical evidence to suggest that gene polymorphisms of sirtuin-1 affect patient susceptibility to DN (Table 1). Maeda et al. discovered that single nucleotide polymorphisms (SNPs) in the SIRT1 gene (encoding sirtuin-1),
but not in the genes encoding other sirtuin family members (sirtuins-2–6), are associated with DN in Japanese T2DM patients [17]. Tang et al. investigated the associations between DN and SNPs in p300 and SIRT1 in Chinese patients with T2DM [18], and demonstrated that the SIRT1 rs4746720 allele C was associated with the urinary albumin/creatinine (Alb/Cre) ratio. P300 allele G and the SIRT1 TC genotype are associated with the development of DN, while the G and TT genotypes predispose to more severe DN. Another study of 1066 Han Chinese with T2DM showed that patients with the SIRT1 rs10823108 AA genotype had a lower risk of developing DN [8]. These associations between SIRT1 gene polymorphisms and DN suggest that sirtuin-1 is implicated in the initiation of DN.

A number of models of diabetes have been used to evaluate the renoprotective effects of sirtuin-1, including both T1DM [20, 21] and T2DM models [22, 23], such as the db/db diabetic mouse, streptozotocin (STZ) alone diabetic mouse/rat model, or a combination of STZ- and high-fat diet-induced diabetic mouse/rat models. To identify the role of sirtuin-1 in the kidney, Chuang et al. generated mice with an 80% reduction in sirtuin-1 expression [24], which showed no defect in glomerular function until they were rendered diabetic, when they demonstrated severe albuminuria and mitochondrial dysfunction. In addition, Hasegawa et al. used proximal tubule–specific sirtuin-1 transgenic and sirtuin-1 knockout mice to reveal that sirtuin-1 protects against albuminuria in diabetes [25]. Finally, podocyte-specific knockout of sirtuin-1 reduced the quality and quantity of podocytes and worsened albuminuria in diabetic mice [26].

In vitro, renoprotective effects of sirtuin-1 are studied in primary renal parenchymal cells and cell lines in the presence of high concentrations of glucose (HG) or AGEs.

### Podocytes

Apoptosis and the detachment of podocytes, and foot process effacement, cause albuminuria in DN. Multiple studies show that sirtuin-1 is necessary for the maintenance of cytoskeletal integrity and the survival of podocytes [27, 28]. A model of non-diabetic podocyte injury (induced by a nephrotoxic serum) revealed that sirtuin-1 can deacetylate cortactin, which is crucial for the maintenance of the actin cytoskeleton and the structure of the slit diaphragm between podocyte processes [27]. Treatment with AGE-modified bovine serum albumin downregulated sirtuin-1 in cultured podocytes, which increased the acetylation of forkhead box group O (FoxO)4, resulting in apoptosis because of greater expression of the pro-apoptotic gene BCL2 like 11 [29]. Hasegawa et al. referred to “proximal tubule-podocyte communication,” by which sirtuin-1 in tubules downregulates claudin-1 expression in podocytes to protect against diabetes-induced albuminuria [25, 30]. Claudin-1 belongs to the claudin family of proteins that constitutes the tight junction. High levels of claudin-1 have been reported to be associated with podocyte effacement and albuminuria. Sirtuin-1 downregulates the expression of claudin-1 by deacetylating histone H3 and H4. Conversely, diabetes-induced upregulation of claudin-1 in podocytes causes slit diaphragm-tight junction transition and consequently proteinuria [31]. The potential mechanism of this

| Race          | Case load                           | Type of diabetes | The role of sirtuin-1 in DN                                                                 | References |
|---------------|-------------------------------------|------------------|---------------------------------------------------------------------------------------------|------------|
| Japanese      | Study 1: 747 overt proteinuria cases vs. 557 controls; Study 2: 455 overt proteinuria cases vs. 965 controls; Study 3: 300 end-stage renal disease cases vs. 218 controls | T2DM             | SNP rs4746720 in sirtuin-1 is significantly associated with proteinuria, and rs2236319, rs10823108, rs3818292, and rs4746720 are associated with combined phenotypes (proteinuria and ESRD). | [17]       |
| Chinese       | DM with DN 628 cases vs. DM without DN 388 cases | T2DM             | rs20551 G alleles in p300 and rs4746720 C alleles in SIRT1 correlate with an increase in ACR. P300 allele G and the sirtuin-1 TC genotype are associated with the development of DN, while the G and TT genotypes predispose to more severe DN. | [18]       |
| Chinese       | 653 DM with DN vs. 413 without DN    | T2DM             | SIRT1 rs10823108 AA genotype is associated with a decreased risk of DN.                     | [8]        |
| Chinese       | 495 DM patients:                   | T2DM             | Serum Sirtuin-1 levels of diabetes patients are significantly lower than those in the control group, and decrease with the increase in ACR. | [19]       |
|               | Normoalbuminuric group (ACR < 30 mg/g, n = 186) |                  |                                               |            |
|               | Microalbuminuric group (ACR 30–300 mg/g, n = 169) |                  |                                               |            |
|               | Macroalbuminuric group (ACR > 300 mg/g, n = 140) |                  |                                               |            |

SNP, single nucleotide polymorphism; DM, diabetes mellitus; DN, diabetic nephropathy; ACR, urinary albumin to creatinine ratio

---

Table 1 The role of sirtuin-1 in clinical studies of diabetic nephropathy

---

J Mol Med (2019) 97:291–309 293
proximal tubule-podocyte communication will be discussed below.

**Glomerular mesangial cells**

Glomerular mesangial cells (GMCs) secrete numerous cytokines under diabetic conditions, including transforming growth factor-β1 (TGF-β1), leading to the expansion of the mesangial area and glomerular sclerosis. Under these conditions, a reduction in sirtuin-1 of GMCs has been observed, which leads to inflammation and fibrosis [32]. Normally, sirtuin-1 blocks the activation of pro-hypertrophic Akt signaling, as well as augmenting the activity of anti-hypertrophic AMP-activated protein kinase (AMPK) signaling in GMCs [33]. However, sirtuin-1 protein levels and deacetylase activity decline in a dose- and time-dependent manner in GMCs cultured with AGEs [34]. Furthermore, in a rat glomerular mesangial cell line that was exposed to HG for 72–144 h, the expression of sirtuin-1 decreased, while expression of the renal pro-fibrotic factors vimentin and fibronectin (FN) was induced [35].

**Renal ECs**

Although studies regarding the role of sirtuin-1 in diabetic endothelial injury have been few in number, they do provide evidence that changes in sirtuin-1 expression in ECs also involve DN. Mice with an endothelium-specific deletion of sirtuin-1 show peritubular capillary rarefaction and fibrosis, due to activation of notch-1 signaling [36]. Moreover, the cleavage of sirtuin-1 by cathepsin is involved in stress-induced premature senescence in ECs [37]. Dermal-derived human microvascular ECs incubated in HG medium show early senescence and develop an irregular and hypertrophic phenotype, associated with lower sirtuin-1 mRNA expression [38]. In addition, in human glomerular ECs exposed to HG, AMPK phosphorylation (pAMPK) and sirtuin-1 expression were lower and there was more apoptosis [39].

**Proximal tubular cells**

Lower sirtuin-1 expression was observed in proximal tubular cells (PTCs), which are fragile parenchymal cells, under HG conditions. Fu et al. reported that the mRNA and protein expression of sirtuin-1 by PTCs incubated in HG decreased to 19% and 36% of the control level, respectively [40]. Xue et al. showed similar time-dependent reductions in HK-2 cells (a PTC cell line) [41]. Studies by Hasegawa et al. revealed that sirtuin-1 expression in PTCs affects glomerular function by influencing podocytes. They found that sirtuin-1 expression in PTCs is low prior to the appearance of albuminuria in STZ-induced or db/db diabetic mice. PTC-specific knockout of sirtuin-1 causes albuminuria in non-diabetic mice and aggravates the albuminuria of diabetic mice. Furthermore, PTC-specific sirtuin-1 transgenic mice are protected against DN [25]. They called this phenomenon “proximal tubule-podocyte communication” and proposed that HG stress triggers a decline in sirtuin-1 expression in proximal tubules, leading to the release of the humoral mediator nicotinamide mononucleotide (NMN), which causes an increase in claudin-1 expression in podocytes [30]. NMN is a NAD+ intermediate, which is found at a lower concentration in the medium of PTCs incubated in HG than in that of PTCs incubated with a normal concentration of glucose. When the medium from PTCs incubated in HG was used to culture podocytes, the podocytes exhibited downregulation of sirtuin-1 and upregulation of claudin-1, whereas the levels of sirtuin-1 and claudin-1 did not change when the podocytes were incubated in HG medium alone. These findings indicate that some factors (NMN, not HG) in the conditioned medium from HG-incubated PTCs affect the expression of sirtuin-1 and claudin-1 in podocytes [25]. Finally, a fluorescence-labeling technique showed that NMN could be released by PTCs and affect podocytes [30].

**Roles of sirtuin-1 in signaling**

**AMPK/sirtuin-1/PGC-1α signaling**

Under diabetic conditions, the downregulation of AMPK/sirtuin-1/PGC-1α signaling induces hypertrophy, OS, and mitochondrial and autophagy dysfunction, all which promote the development of DN (Fig. 1). Both AMPK and sirtuin-1 have been identified as intracellular energy sensors, detecting and responding to AMP/ATP and NAD+/NADH ratios, respectively, and therefore being activated under conditions of energy depletion and deactivated in diabetes [42–44]. However, AMPK and sirtuin-1 also regulate one another’s activity [42]. Sirtuin-1 deacetylates lysine residues in liver kinase B1 (LKB1), promoting its migration from the nucleus to the cytoplasm, where it can catalyze the phosphorylation and activation of AMPK [45]. Concurrently, AMPK activates downstream signaling in a sirtuin-1–dependent manner [46]. In addition, AMPK upregulates sirtuin-1 by increasing cellular NAD+ levels [47]. Finally, Fulco et al. showed that glucose restriction–induced activation of AMPK increases sirtuin-1 activity by promoting transcription of the NAD+ biosynthetic enzyme nicotinamide phosphoribosyltransferase (Nampt) [48].

Under diabetic conditions, pAMPK was lower in glomeruli and tubules, implying the inactivation of AMPK [49, 50]. Previous studies showed that calorie restriction (CR) has beneficial effects on DN via AMPK and sirtuin-1 [51]. The levels of pAMPK and sirtuin-1 are lower in diabetic kidney, but the phosphodiesterase type 4 (PDE4) inhibitor roflumilast mimics
the effects of CR to restore the levels of pAMPK/sirtuin-1 and alleviate DN [52]. AMPK and sirtuin-1 share peroxisome proliferator−activated receptor (PPAR)-γ coactivator 1α (PGC-1α) as a target, which is a transcriptional coactivator that modulates metabolic homeostasis [53], and mitochondrial biogenesis and function [54]. It has been suggested that the phosphorylation of PGC-1α by AMPK makes it more susceptible to deacetylation by sirtuin-1 [47] and enhances its ability to activate its own promoter [55].

Adiponectin is an adipokine that has protective antioxidant and anti-inflammatory effects, but its expression is downregulated in IR, obesity, and T2DM. The receptors of adiponectin include adiponectin receptor (AdipoR)1 and AdipoR2, which activate AMPK and PPARα. Resveratrol, an activator of sirtuin-1, promotes the phosphorylation of AMPK and the activation of sirtuin-1/PGC-1α signaling, which prevents apoptosis and OS, and thereby ameliorates DN in db/db mice [56]. In addition, Park et al. reported that HG-induced OS and apoptosis in cultured glomerular ECs are prevented by resveratrol treatment, which activates AMPK/sirtuin-1/PGC-1α and PPARα signaling by increasing the expression of AdipoR1 and AdipoR2 [39].

Furthermore, several natural substances have been identified to ameliorate DN by activating AMPK/sirtuin-1/PGC-1α signaling. In vitro, glycyrrhizic acid attenuates cell proliferation and TGF-β1 overexpression, and ameliorates the low expression and activity of AMPK, sirtuin-1, and manganese superoxide dismutase (Mn-SOD) induced by HG in renal
tubular cells [57]. In vivo, glycyrrhizic acid ameliorates DN by inhibiting ROS and activating AMPK/sirtuin-1/PGC-1α signaling in db/db mice [22]. Cai et al. reported that grape seed procyanidin B2 upregulated the expression of AMPK, sirtuin-1, and PGC-1α in podocytes [58], while Bao et al. showed that grape seed proanthocyanidin prevents diabetes-induced OS and mitochondrial dysfunction in podocytes by activating AMPK/sirtuin-1/PGC-1α signaling [59].

Sirtuin-1 and mammalian target of rapamycin

Decreases in sirtuin-1 expression alleviate suppression of the mTOR pathway, which promotes HG-induced renal cell autophagy dysfunction and senescence. Mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase and component of the mTOR complex, which is a key modulator of cellular proliferation, autophagy, and lipid metabolism. Tuberous sclerosis complex (TSC)1 and TSC2 are inhibitors of the mTOR signaling pathway, and it is reported that the negative regulation of mTOR signaling by sirtuin-1 is TSC2-dependent. Immunoprecipitation indicated that sirtuin-1 interacts with TSC2, but the exact mechanism is uncertain [60]. HG induces the upregulation of mTOR and downregulation of sirtuin-1 in MCs [61], while rapamycin, an inhibitor of mTORC1, inhibits the downstream pathway and arrests HG-induced MC senescence. However, the silencing of sirtuin-1 completely inhibits the effects of rapamycin in HG-treated MCs. These findings suggest that sirtuin-1 regulates the mTOR pathway, which mediates the induction of MC senescence by HG [61]. Another study confirmed that rapamycin partially inhibits mTORC1 and restores sirtuin-1 activity in palmitate-treated podocytes [62].

Sirtuin-1 and the Keap1/Nrf2/ARE pathway

The activation of the nuclear factor erythroid 2–related factor 2 (Nrf2)/anti-oxidant response element (ARE) pathway is suppressed in DN due to low sirtuin-1 levels, which in turn decreases anti-oxidant capacity. Accumulation of AGEs in diabetic kidney stimulates the generation of ROS, causing OS and promoting the progression of DN. ROS/anti-oxidant homeostasis is disturbed when the production of ROS exceeds the production of anti-oxidants, and diabetic complications result from OS due both to excessive production of ROS and a reduction in anti-oxidant capacity [13].

The Nrf2 is a transcription factor that binds to the ARE of DNA and switches on its target genes, including NAD(P)H quinone dehydrogenase 1 (NQO-1), heme oxygenase 1 (HO-1), and superoxide dismutase (SOD). Kelch-like ECH–associated protein 1 (Keap1) acts as a negative regulator of Nrf2 by binding it, blocking its transfer to the nucleus, and promoting its degradation. The Nrf2/ARE pathway is a critical cellular anti-oxidant mechanism that is inactivated during chronic OS, including that associated with diabetes, and sirtuin-1 has a significant anti-oxidant effect because it activates the Nrf2/ARE pathway [63, 64]. Previous studies demonstrated cross-talk between sirtuin-1 and the Keap1/Nrf2/ARE pathway: sirtuin-1 enhances the activity of the Keap1/Nrf2/ARE pathway by decreasing Keap1 expression, deacetylating and reducing the ubiquitination of Nrf2, and promoting ARE-binding ability in AGE-treated GMCs [65]. In addition, Huang et al. reported that polydatin, a glucoside of resveratrol, ameliorates AGE-induced FN and TGF-β1 expression by activating the sirtuin-1/Nrf2/ARE pathway in rat GMCs [64]. Zhang et al. reported that paeonol, an extract of Cortex moutan, delayed the progression of fibrosis by activating sirtuin-1 and therefore the Nrf2 pathway in DN [66]. Ling Zhou et al. found that HG decreased sirtuin-1 activity in HK-2 cells, enhanced Keap1 expression, and promoted the ubiquitination and degradation of Nrf2 via a pathway involving NF-κB and microRNA (miR)-29 [67]. However, Nrf2 also positively regulates the protein expression of sirtuin-1 [65], and the Nrf2 activator tBHQ increases the expression and deacetylase activity of sirtuin-1, while small interfering (si)RNAs targeting Nrf2 reduce sirtuin-1 expression and activity, leading to greater expression of FN and TGF-β1 in GMCs [65]. Although the underlying mechanism of these effects is unknown, some studies show that Nrf2 promotes sirtuin-1 expression by negatively regulating p53 [68].

Sirtuin-1 and p66Shc

Diabetes-induced downregulation of sirtuin-1 increases OS in mitochondria by promoting histone H3 and p66Shc acetylation. Mitochondria are the primary source of the excess ROS [13]. The adaptor protein 66 kDa Src homology 2 domain–containing protein (p66Shc) is a crucial regulator of mitochondrial ROS production and contributes to DN by promoting OS [69–71]. p66Shc mainly expresses in the renal tubular cells and glomeruli and is a direct target of sirtuin-1. A recent study indicates that HG-induced downregulation of sirtuin-1 promotes the expression of p66Shc by increasing histone H3 and p66shc acetylation [72]. Histone H3 acetylation promotes transcription of p66Shc. The acetylation of p66Shc facilitates its phosphorylation and translocation to mitochondria, where it promotes hydrogen peroxide production [69, 73, 74]. In addition, diabetes, HG, and palmitate stimulate p66Shc, which activates a redox mechanism that upregulates miR-34a expression, targeting sirtuin-1 for degradation, and causing endothelial dysfunction. These effects are prevented when p66shc expression is silenced, while overexpression of p66Shc enhances HG and palmitate-induced miR-34a expression, thus reducing that of sirtuin-1 [75].
Sirtuin-1 and HIF-1

Sirtuin-1 deficiency under diabetic condition leads to activation of HIF-1, which results in abnormal angiogenesis and fibrosis in the kidney. Recent studies demonstrated that hypoxia is also involved in the pathogenesis of DN [14]. Hyperfiltration or and metabolic changes in diabetic kidneys cause excessive oxygen consumption, resulting in hypoxia and expression of the oxygen sensor HIF-1. HIF-1 is composed of a functional α-subunit and a constitutive β-subunit and promotes epithelial-to-mesenchymal transition (EMT) in vitro, while renal epithelial knockout of HIF-1α prevents tubulointerstitial fibrosis [76]. HIF-1α is a downstream target of sirtuin-1, and during hypoxia downregulation of sirtuin-1 leads to greater acetylation and activation of HIF-1α. When sirtuin-1 is activated by resveratrol, HIF-1α is deacetylated and inactivated, which prevents HG-induced expression of connective tissue growth factor (CTGF), endothelin-1, FN, TGF-β1, and VEGF [32].

Sirtuin-1 and NF-κB

Diabetes-induced downregulation of sirtuin-1 leads to activation of NF-κB signaling, which promotes the activation of downstream pro-inflammatory factors and inhibits anti-oxidative stress Nrf2/ARE pathway involved in the development of DN. NF-κB is a transcription factor that governs the expression of genes involved in inflammation. The canonical pathway of NF-κB activation involves the p65 and p50 subunits [77], and it is now known that sirtuin-1 can deacetylate the p65 subunit of NF-κB and inhibit NF-κB pro-inflammatory signaling and the downstream production of MCP-1, ICAM-1, and VCAM-1 [77–79]. MCP-1 exerts pro-inflammatory effects by regulating the migration and infiltration of monocytes/macrophages, a process that could thus be regulated by a sirtuin-1/NF-κB p65 pathway [80]. Podocyte-specific ablation of sirtuin-1 in db/db mice results in severe proteinuria and kidney injury, which is accompanied by greater acetylation of p65 and STAT3 [26]. NADPH oxidase 4 (NOX4) expression is higher in DN, while podocyte-specific knockout of NOX4 attenuates DN. Previous studies suggest that NF-κB directly regulates NOX4 expression by binding to its promoter, and sirtuin-1 could therefore ameliorate inflammation in DN, at least in part through deacetylation of NF-κB and downregulation of NOX4 [81]. NF-κB could also interact with the Nrf2/ARE pathway via sirtuin-1 and miR-29. In support of this, Zhou et al. found that, in HG-incubated tubular epithelial cells, downregulation of sirtuin-1 increased the acetylation and activity of NF-κB, which directly binds to the promoter and downregulates miR-29 expression, thereby increasing the expression of Keap1 and inhibiting the Nrf2/ARE pathway [67].

Sirtuin-1 and FOXO

Sirtuin-1 deacetylates FOXO, which changes the transcriptional activity of FOXO target genes to prevent OS, inflammation, and apoptosis in DN. FOXO belongs to the forkhead family of transcription factors, which have a conserved DNA-binding domain. In mammals, four family members have been identified: FoxO1, FoxO3a, FoxO4, and FoxO6. The expression of FoxO1 and FoxO3a is ubiquitous, while FoxO4 is highly expressed in the muscle and heart and FoxO6 is expressed in the brain [82]. Acetylation both promotes and reduces FOXO transcriptional activity and mediates various biological functions of FOXO [83].

FoxO1 has been extensively studied and shown to regulate cellular events, such as metabolism, proliferation, redox status, stress resistance, inflammation, aging, and apoptosis [84]. Sirtuin-1 reduces the acetylation of FoxO1, which enhances the DNA-binding affinity of FoxO1 [85]. The sirtuin-1/FoxO1 pathway has an anti-oxidant effect because it increases expression of Mn-SOD and catalase (CAT) [86, 87]. However, the expression of FoxO1 is lower, which is associated with the accumulation of extracellular matrix (ECM) and OS in type 1 diabetic kidney. Xu et al. found that puerarin upregulated the expression of sirtuin-1, FoxO1, and PGC-1α in renal cortex and was therefore protective against DN [87]. In addition, treatment of DN with the sirtuin-1 agonist resveratrol increased SOD activity and reduced MDA, collagen IV, and FN expression by increasing FoxO1 activity [88].

FoxO3a regulates cellular processes, including metabolism, cellular proliferation and differentiation, OS resistance, inflammation, aging, and apoptosis [84]. Sirtuin-1 deacetylates FoxO3a, which enhances FoxO3a-induced autophagy and anti-oxidant effects, while suppressing FoxO3a-induced cell death. Resveratrol deacetylates FoxO3a and attenuates the OS caused by hyperglycemia, both in vivo and in vitro. Silencing sirtuin-1 induces overexpression of acetylated FoxO3a, which aggravates the OS in HG-induced tubular epithelial cells; resveratrol treatment fails to protect against these effects [89]. Sirtuin-1 activates autophagy by deacetylating FoxO1 and FoxO3a in the nucleas [90–92], the mechanisms of which will be described below.

In addition to FoxO1 and FoxO3a, FoxO4 is deacetylated by sirtuin-1. It is involved in cellular proliferation, inflammation, aging, and apoptosis in mammals [84]. AGEs cause podocyte apoptosis by downregulating sirtuin-1 and increasing acetylation of FoxO4, which promotes expression of BCL2 like 11 [29].

Sirtuin-1 and p53

Diabetes-induced decreases in sirtuin-1 expression involve apoptosis via activation of the p53 pathway. Apoptosis of podocytes, ECs, and tubular epithelial cells causes
albuminuria and renal dysfunction in DN. Sirtuin-1 exerts anti-apoptotic effects to protect against cellular injury by deacetylating pro-apoptotic proteins. p53 is a tumor suppressor gene that is activated and induces cell cycle arrest or apoptosis under DNA-damaging conditions [93]. Acetylation stabilizes and activates p53, promoting target gene transcription, including that of p21 and Bax [93]. Sirtuin-1 negatively regulates p53 by deacetylating it at the C-terminal lysine-382 residue, and this relationship between sirtuin-1 and p53 is closely associated with aging and diabetes [93]. The sirtuin-1/p53 pathway has also been implicated in HG-induced apoptosis: study of cultured PTCs has shown that incubation in HG reduces sirtuin-1 protein expression and increases the expression of c-caspase-3 and c-PARP, and the acetylation of p53, especially when small interfering RNA against sirtuin-1 is used [94]. In addition, resveratrol prevented increases in expressions of p38 and p53, the dephosphorylation of histone H3. PTC apoptosis, and albuminuria in DN by activating sirtuin-1 [94, 95]. A recent study suggested that a p53/miR-155-5p/sirtuin-1 loop is present in the kidney of animals with DN: p53 promoted the expression of miR-155-5p, which reduced sirtuin-1 expression, in turn downregulating sirtuin-1 and disinhibiting p53 [96].

**Sirtuin-1 and autophagy-related proteins**

Decreases in sirtuin-1 expression inhibit autophagy under diabetic conditions by suppressing the expression of autophagy-related proteins, FOXO and AMPK, and activating mTOR. Autophagy is a regulated process that disassembles and recycles unnecessary or dysfunctional cellular components. The process of macroautophagy, the most intensively investigated type of autophagy, includes phagophore formation and elongation, autophagosomal formation, lysosome fusion, and degradation in autolysosomes [97]. Autophagy-related (Atg)5, Atg7, and Atg8 are required for the formation and elongation of the autophagosomal membrane, while microtubule-associated protein light chain 3 (LC3) and pro-autophagic Beclin1/adenovirus E1 V19 kDa interacting protein 3 (Bnip3) are necessary for autophagy. Under starvation conditions, sirtuin-1 promotes the activity of FoxO1 and FoxO3a, which are localized to the nucleus and bind to promoter sequences of Atg8 and Atg12 [90]. Deacetylation of LC3 by sirtuin-1 promotes its nucleocytoplasmic transport and the formation of autophagosomes [98]. An increasing body of evidence indicates that a deficiency in autophagy contributes to the pathogenesis of DN [99–102]. Sirtuin-1 may restore autophagy by deacetylating FoxO1 and FoxO3 in the nucleus [90–92] and Atg5, Atg7, and Atg8 in the cytosol [103]. Activation of sirtuin-1 restores the expression of FoxO3, which positively regulates Bnip3, and thus enhances autophagy in the kidneys of db/db mice [7]. Knockdown of sirtuin-1 inhibits Atg7, Atg5, and LC3, and abolishes the resveratrol-mediated amelioration of the defect in autophagy induced by hypoxia in cultured PTCs [7]. Furthermore, both the AMPK and mTOR pathways regulate autophagy. AMPK is a positive regulator of autophagy, while the mTOR pathway is a negative regulator, activating or inhibiting UNC51-like kinase 1 complex, which is essential for the initiation of autophagy [104, 105]. Indeed, the impaired autophagy observed in DN is associated with defects in both the mTOR and AMPK pathways. Thus, sirtuin-1 might regulate autophagy via mTOR and AMPK in diabetic kidneys. Recently, a study showed that a p53/miR-155-5p/sirtuin-1 pathway regulates autophagy in PTCs incubated in HG [96], which will be discussed further below.

**Sirtuin-1 and TGF-β1/smад pathway**

Sirtuin-1 prevents diabetic renal fibrogenesis by inhibiting TGF-β1/small mothers against decapentaplegic homolog (smad) 2/3 pathway. Tubulointerstitial fibrosis and renal dysfunction are pathological features of the end stage of various kidney diseases, including DN. There is increasing evidence of the anti-fibrotic effects of sirtuin-1 in experimental models of diabetes. TGF-β1 is a pro-fibrogenic factor that is upregulated in DN; it binds to its receptor and activates the downstream mediators smad 2/3 [106, 107]. Phosphorylation and acetylation of smad2/3 enhance their activity and cause accumulation of ECM, including of collagen and FN [106–109]. However, smad2/3 have also been identified as targets of sirtuin-1. Recent studies report that TGF-β1 promotes smad2/3 acetylation, while resveratrol treatment deacetylates smad3 by activating sirtuin-1 in cultured PTCs [110]. In addition, resveratrol administration abolishes TGF-β1/smad3-induced renal fibrosis in a mouse model of unilateral ureteral obstruction. In subtotally or 5/6 nephrectomized rat models, sirtuin-1 activator SRT3025 attenuated TGF-β1 overexpression, GFR decline, and proteinuria [108]. However, studies investigating whether sirtuin-1 can prevent renal fibrogenesis in DN through TGF-β1/smad2/3 deacetylation have not been reported [110]. Another study revealed reduced sirtuin-1 and increased acetylase p300, TGF-β1, and collagen I expression in HG-incubated microvascular ECs [111]. Diabetes caused high TGF-β1 expression in the kidney and albuminuria was blunted in sirtuin-1 overexpressing transgenic mice.

**Sirtuin-1 and STAT3**

Signal transducer and activator of transcription3 (STAT3) are transcription factors, which are activated under diabetic conditions. The transcriptional activity of STAT3 is negatively regulated by sirtuin-1. A study by Liu et al. revealed that phosphorylation and acetylation of p65 and STAT3 were higher in the glomeruli of db/db mice than in those of db/m mice [26]. They also confirmed that acetylation of p65 and
STAT3 is required for their transcriptional activity by mutating the acetylated residues. Knockout of sirtuin-1 in podocytes significantly increased acetylation of p65 and STAT3 and the mice were more susceptible to DN.

**Sirtuin-1 and VEGF mediate angiogenesis**

Reduced sirtuin-1 expression results in angiopoietin 2, VEGF, and Flk-1 upregulation, which eventually leads to abnormal angiogenesis in DN. Abnormal angiogenesis occurs in the kidneys of patients and animal models with DN. Emerging evidence demonstrates that abnormal angiogenesis is associated with glomerular hypertrophy and plasma leakage, which play a pathological role in DN [112]. VEGF is a pro-angiogenic factor that binds to its receptor VEGFR-2 (KDR/Flk-1) and generates angiogenic signals by dimerization and phosphorylation of VEGFR-2 [113]. Angiopoietins are vascular growth factors, including angiopoietin 1 (effective factor) and angiopoietin 2 (antagonist of angiopoietin 1). Angiopoietin 1 and angiopoietin 2 competitively bind to their receptor tie-2 (tyrosine kinase with Ig and EGF homology domain 2). High concentrations of angiopoietin 2 and VEGF promote endothelial proliferation and plasma leakage, whereas apoptosis is induced when the upregulation of angiopoietin 2 is not paralleled by that of VEGF [114]. It is reported that VEGF, Flk-1, and angiopoietin 2 are upregulated in DN, and the upregulation of sirtuin-1 in cultured ECs reduces Flk-1 expression. In addition, resveratrol has beneficial effects in cultured podocytes and ECs by ameliorating the HG-induced expression of VEGF and Flk-1, but these effects are abolished by knocking down sirtuin-1 [115]. These findings suggest that sirtuin-1 can attenuate abnormal angiogenesis in DN by modulating VEGF, Flk-1, and angiopoietin 2.

**Sirtuin-1 and the renin-angiotensin system**

Downregulation of sirtuin-1 is involved in DN partly via its interacting with RAS. Inhibition of the renin-angiotensin system (RAS) benefits diabetic and DN patients, which indicates that the RAS is involved in the progression of DN. Angiotensin II (Ang II) is the principal effector of the RAS, but angiotensin-converting enzyme 2 (ACE2) counteracts the effects of Ang II by hydrolyzing Ang II to form angiotensin 1–7, which is protective against DN [116]. There is some evidence to suggest that sirtuin-1 interacts with the RAS: sirtuin-1 targets and activates the ACE2 promoter [116, 117], while Ang II regulates sirtuin-1 expression and activity. The expression of sirtuin-1 declines and the acetylation of p53 increases in a time-dependent fashion in Ang II–treated podocytes. Olmesartan, an angiotensin receptor blocker, is reported to increase sirtuin-1 activity, and to reduce p53 acetylation and p38 phosphorylation in the kidneys of diabetic db/db mice [118]. Furthermore, angiotensin 1–7 could protect against DN in db/db mice by increasing sirtuin-1 expression [116].

**Endogenous factors regulate sirtuin-1 in diabetic nephropathy**

**Nampt and sirtuin-1**

Metabolism of glucose and fatty acids produces NADH, which results in a reduction in the NAD+/NADH ratio under conditions of nutrient excess, such as diabetes, and is also associated with a reduction in the expression of sirtuin-1. Nampt is a key enzyme catalyzing NAD+ biosynthesis. Endogenous Nampt expression in the kidneys of STZ-induced diabetic rats was reported to be 2.36-fold higher than that of control rats [35], and immunohistochemistry demonstrated that Nampt is localized to the glomerular and tubular cells of diabetic rats [119]. In vitro, progressively higher expression of Nampt, NF-κB p65, FoxO1, and Bax, and progressively lower expression of sirtuin-1, were observed in the glomerular mesangial HBZY-1 cell line when it was exposed to HG conditions, which induced excessive expression of vimentin and FN [35].

**Heterogeneous nuclear ribonucleoprotein F and sirtuin-1**

Heterogeneous nuclear ribonucleoprotein F (hnRNP F) belongs to the pre-mRNA-binding protein family and regulates gene expression at transcriptional and post-transcriptional levels. It was reported that the expression of hnRNP F, sirtuin-1, and FoxO3a was lower in human type 2 diabetic kidneys than non-diabetic kidneys. Overexpression of hnRNP F leads to higher levels of binding to the sirtuin-1 promoter, activating transcription, and leading to the attenuation of OS in PTCs, tubulointerstitial fibrosis, and apoptosis in db/db mice, because of deacetylation of Foxo3a and p53, and greater expression of CAT [120].

**MicroRNAs and sirtuin-1**

miRNAs are 21–25 nucleotide–long non-coding RNAs that regulate target gene expression by binding to their 3’-untranslated regions (UTRs), causing degradation or repressing their translation. Accumulating evidence demonstrates that specific miRNAs contribute to the pathogenesis of DN by targeting sirtuin-1 mRNA (Fig. 2).

miR-34a-5p has been identified to suppress sirtuin-1 by directly targeting its 3’-UTR. When miR-34a-5p expression is high, sirtuin-1 expression falls, increasing the expression of the pro-fibrogenic factor TGF-β1, FN, and collagen type I in the kidneys of high-fat diet and STZ-induced diabetic mice.
It is also known that long non-coding RNAs (lncRNAs) can interact with miRNAs. 1700020I14Rik (ENSMUST00000147425) is a lncRNA that directly targets miR-34a-5p and interacts with it in an Ago2-dependent manner. Downregulation of 1700020I14Rik has been shown to promote proliferation and fibrosis via a miR-34a-5p/sirtuin-1 pathway in MCs [121].

Recently, a clinical study suggested that urinary miR-377 could be used as an early biomarker of DN in pediatric T1DM. The urinary miR-377 level is higher in T1DM patients with microalbuminuria, than in both normoalbuminuric patients and healthy controls [122]. HG triggers the upregulation of miR-377 in GMCs, which inhibits PPARγ expression and promotes plasminogen activator inhibitor-1 (PAI-1) and TGF-β1 expression [123]. miR-377 was identified to target the 3'-UTR of sirtuin-1 mRNA directly and reduces sirtuin-1 protein abundance in the adipose tissue of high-fat diet–fed mice [124]. However, further studies regarding the role of the interaction between miR-377 and sirtuin-1 in the pathogenesis and development of DN are required.

Another clinical study showed that miR-217 closely correlates with the severity of DN in patients with T2DM. Serum miR-217 levels positively correlate with the severity of albuminuria and negatively correlate with sirtuin-1 expression in patients with T2DM [19]. In addition, the study by Shao et al. showed that miR-217 expression increases in HG-treated rat GMCs. By contrast, silencing miR-217 or resveratrol treatment promotes the expression of sirtuin-1, which results in lower expression of HIF-1α and ameliorates HG-induced increases in CTGF, endothelin-1, FN, TGF-β1, and VEGF expression in rat GMCs [32].

Recently, miR-155-5p has become of interest due to its effects on renal tubule injury as part of a p53/miR-155-5p/sirtuin-1 pathway. Baker et al. measured the expression of this miRNA in the glomeruli and proximal tubules of 98 patients and discovered that miR-155-5p expression is high in the proximal tubules of individuals with DN, and in membranoproliferative glomerulonephritis and focal segmental glomerulosclerosis [125]. Bioinformatic analysis predicted the existence of binding sites of miR-155-5p on sirtuin-1 mRNA, and Wang et al. confirmed the presence of a p53/miR-155-5p/sirtuin-1 pathway in tubule cells incubated in HG medium [96].

**Ubiquitin-specific protease 22 and sirtuin-1**

AGEs regulate sirtuin-1 expression by enhancing its ubiquitination and proteasome-mediated degradation. Ubiquitin-specific protease 22 (USP22) reduces the degradation of sirtuin-1 and the expression of FN and TGF-β1 in AGE-treated GMCs, whereas depletion of USP22 promotes sirtuin-1 degradation and the expression of FN and TGF-β1 in this cell model. Therefore, an AGE/USP22/sirtuin-1 pathway may be involved in the pathological progression of DN [126].

In addition to the above, caspase1, Ang II, and cyclin-dependent kinase 5 (CDK5) have been shown to regulate the
level and activity of sirtuin-1 in other tissue and models, indicating that they are probably also involved in the development of DN. Caspase 1 is a member of the cysteine protease caspase family, which is activated by the “inflammasome” and required for the cleavage of multiple substrates, such as IL-1β, II-18, and sirtuin-1; thus, it is probably also involved in atherosclerosis and DN [127, 128]. One study suggested that activation of caspase 1 decreases the level of sirtuin-1 by cleaving sirtuin-1 and promotes pro-inflammatory cytokine activation in the ECs of the aorta of ApoE−/− mice fed a high-fat diet, resulting in the activation of ECs and the initiation of vascular inflammation [127]. Knockout of caspase 1 increased sirtuin-1 levels and decreased aortic monocyte recruitment. Whether caspase-1 involves in DN via regulating sirtuin-1 is required to study. As mentioned in the section of sirtuin-1 and RAS, Ang II regulates sirtuin-1 expression and activity. A study from Huang found that Ang II activated JKN and subsequently led to sirtuin-1 degradation, which enhanced insulin-like growth factor receptor II signaling during Ang II cardiace hypertrophy and apoptosis [129]. Ang II time dependently reduced sirtuin-1 expression and induced apoptosis of cultured podocytes, which was reversed by the AT1 blocker olmesartan [118]. CDK5 is a serine/threonine kinase that phosphorylates sirtuin-1 and inhibits the anti-senescence and anti-inflammatory activity of sirtuin-1 [130]. Phosphorylation of sirtuin-1 at S47 by CDK5 prevents sirtuin-1 nuclear exportation and association with the telomeric repeat–binding factor 2–interacting protein 1 in ECs. Recently, the CDK5-dependent ubiquitin-proteasome pathway was reported to mediate the degradation of sirtuin-1 in Parkinson’s disease models. Inhibition of CDK5 blocked sirtuin-1 degradation [131]. Although CDK5 contributes to podocyte apoptosis and renal tubulointerstitial fibrosis in DN [132, 133], it is unknown whether CDK5 suppression reserves DN by blocking sirtuin-1 degradation.

**Treatments targeting sirtuin-1 in diabetic nephropathy**

There is a growing literature describing the therapeutic effects of synthetic drugs and natural compounds on inflammation, OS, apoptosis, and fibrosis in DN, which are exerted through the upregulation or activation of sirtuin-1.

As shown in Table 2, it is clear that several types of kidney cells are responsive to sirtuin-1 activators such as resveratrol. These findings provide a foundation for preclinical and clinical trials targeting sirtuin-1 in diabetic animals and patients with diabetes.

A list of preclinical studies of treatments for DN that target sirtuin-1 is shown in Table 3. These have shown the following effects: (1) a reduction in the urinary Alb/Cre ratio or 24 h urine albumin; (2) an amelioration of renal histopathology; (3) reductions in markers of OS, inflammation, and apoptosis; (4) an improvement in autophagy; and/or (5) prevention of fibrogenesis. Furthermore, we showed that fenofibrate, a PPARα agonist, can stimulate fibroblast growth factor 21/sirtuin-1–dependent autophagy, which can prevent T1DM-induced cardiac damage [145]. We also found that it protects against T1DM-induced nephropathy by activating fibroblast growth factor 21 and Nrf2 pathways, although sirtuin-1 was not implicated in this study [146]. Thus, whether the renoprotective effects of fenofibrate in T1DM are due to the upregulation of sirtuin-1 remains unclear.

A number of substances and plant extracts that have been found to restore sirtuin-1 activity and have renoprotective effects in preclinical models of DN have been prescribed clinically. Of these, resveratrol is one of the most extensively studied sirtuin-1 activators. However, although the protective effects of resveratrol have been shown in vitro and in vivo, its clinical benefits are controversial [147]. A randomized double-blind placebo-controlled trial revealed that 6 months of low-dose or high-dose resveratrol supplementation did not improve arterial pressure, blood glucose, uric acid, adiponectin, or IL-6 in patients with T2DM [148]. By contrast, a study of 66 patients with T2DM showed that resveratrol (1 g/day for 45 days) improved systolic blood pressure, blood glucose, and IR, but not kidney function [149]. This study used creatinine, rather than urinary Alb/Cre, as an index of kidney function, which is probably why a renoprotective effect was not identified. Another randomized double-blind clinical trial evaluated the effects of resveratrol on albuminuria in DN. The 60 patients enrolled, who had DN and albuminuria, were divided into two groups: resveratrol- (500 mg/day) and losartan (an angiotensin receptor blocker, 12.5 mg/day)-treated, and placebo- and losartan (12.5 mg/day)-treated. After 90-day treatment, the urinary Alb/Cre ratio was significantly lower in the resveratrol group, although GFR and serum creatinine were not different. Although sirtuin-1 was not measured in this study, serum anti-oxidant enzymes, such as SOD, CAT, and glutathione peroxidase, and nitric oxide, were significantly higher in the resveratrol group [150].

Grape seed extracts have been shown to protect against diabetes-induced kidney lesions by activating sirtuin-1 in renal cell lines and animal models. A double-blind randomized controlled trial demonstrated that grape seed extracts could benefit T2DM patients with high cardiovascular risk by ameliorating inflammation and OS [151], but renoprotective effects and sirtuin-1 levels were not evaluated in this trial.

Inhibition of the RAS benefits patients with DN. Olmesartan, an angiotensin receptor blocker, has been shown to prevent microalbuminuria in T2DM patients [152]. In vitro and in vivo studies showed that one of its renoprotective effects is to reduce podocyte apoptosis by increasing sirtuin-1 expression [118], although the mechanism has not been identified in humans.
| Drug or natural substances                        | Renal cell                                                                 | Mechanism of renoprotection                                                                                   | Pathway                                                                                                                                       | Reference |
|-------------------------------------------------|----------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| Glycyrrhizic acid                               | HG-treated renal tubular epithelial cell line (NRK-52E)                     | Anti-oxidant, anti-proliferative                                                                          | AMPK/sirtuin-1/PGC-1α signaling, TGF-β1, Mn-SOD                                                                 | [57]      |
| Glucagon-like peptide-1                         | Podocytes cultured in HG medium                                            | Anti-apoptotic, anti-oxidant, anti-inflammatory                                                            | Sirtuin-1, IL-1, IL-6                                                                                                                          | [134]     |
| Grape seed procyanidin B2                       | High-dose glucosamine-treated rat mesangial cell line (HBZY-1)             | Restore mitochondrial function, anti-apoptotic, anti-oxidant                                                | AMPK/sirtuin-1/PGC-1α                                                                                                                           | [135]     |
| Metformin                                       | HG-treated primary podocytes                                               | Improve podocyte insulin resistance and glucose uptake, reduce glomerular filtration barrier permeability  | AMPK, sirtuin-1                                                                                                                                | [136]     |
| Olmesartan                                      | HG-treated conditionally immortalized mouse podocytes                      | Anti-apoptotic                                                                                                | Angiotensin II/p38/sirtuin-1                                                                                                                   | [118]     |
| Probiotic                                       | HG-treated human proximal tubular epithelial cells (HK-2)                  | Anti-oxidant, anti-fibrotic                                                                               | p66Shc, AMPK/sirtuin-1/AcHB                                                                                                                    | [137]     |
| Puerarin (active compound of radix puerariae)    | HG-treated conditionally immortalized murine podocytes                     | Anti-oxidant                                                                                                | Sirtuin-1, NF-κB, NOX4                                                                                                                        | [81]      |
| Polydatin (glucoside of resveratrol)            | Advanced glycation end product–treated glomerular mesangial cells         | Anti-oxidant                                                                                                | Sirtuin-1/Nrf2/ARE                                                                                                                             | [64]      |
| Panax notoginseng saponins                      | HG-treated rat mesangial cells                                             | Anti-inflammatory, anti-oxidant, anti-fibrotic                                                              | Sirtuin-1/NF-κB, PAI-1, TGF-β1, MCP-1, SOD                                                                                                   | [80]      |
| Resveratrol                                     | HG-treated human endothelial cells                                         | Counteract the other pro-atherosclerotic effects, downregulate endothelial nitric oxide synthase            | Sirtuin-1                                                                                                                                     | [138]     |
| HG-treated primary rat mesangial cells           | Anti-senescent                                                            | mTOR, sirtuin-1                                                                                              |                                                                                                                                                | [61]      |
| HG-treated primary rat mesangial cells           | Anti-oxidant, restore mitochondrial function                                | Sirtuin-1, Mn-SOD                                                                                           |                                                                                                                                                | [63]      |
| HG-treated conditionally immortalized mouse podocytes; HG-treated immortalized mouse mesangial cell line | Suppress VEGF expression and secretion in podocytes, suppress Flk-1 expression in glomerular endothelial cells, ameliorate hyperpermeability and cellular junction disruption | Sirtuin-1, VEGF, Flk-1                                                                                                                        | [115]     |
| Advanced glycation end product–treated rat primary glomerular mesangial cells | Anti-oxidant, anti-fibrotic                                                | Sirtuin-1, Nrf2/ARE, TGF-β1                                                                                 |                                                                                                                                                | [34]      |
| HG-treated NMS2 mesangial cells                 | Anti-oxidant, anti-apoptotic                                               | AMPK/sirtuin-1/PGC-1α                                                                                       |                                                                                                                                                | [56]      |
| HG-treated human kidney epithelial (HK-2) cells  | Anti-oxidant                                                              | Sirtuin-1/POXO3a                                                                                             |                                                                                                                                                | [89]      |
| Shenkang injection (composed of Radix Astragali, Rhabarb, Astragalus, Safflower, and Salvia) | Anti-senescent, anti-oxidant                                               | mTOR, p66Shc, sirtuin-1, PPARγ, P16INK4, cyclin D1, SOD                                                |                                                                                                                                                | [40]      |
| Theobromine                                     | HG-treated immortalized human mesangial cells                             | Anti-fibrotic                                                                                                | NOX4, AMPK, sirtuin-1/TGF-β                                                                                                                   | [139]     |
| Tetrahydroxystilbene glucoside (active component of Polygonum multiflorum Thunb) | HG-treated rat mesangial cell line (HBZY-1)                              | Anti-oxidant                                                                                                | Sirtuin-1/TGF-β1, COX-2                                                                                                                        | [140]     |
| Substance                        | Animal model                                      | Mechanism of renoprotection                                                                 | Pathway                                                                 | Reference |
|---------------------------------|---------------------------------------------------|---------------------------------------------------------------------------------------------|------------------------------------------------------------------------|-----------|
| 3,5-Diiodo-L-thyronine           | T1DM: STZ-induced diabetic rat                    | Prevent decrease in sirtuin-1 expression and activity; anti-fibrotic transforming growth factor-β1 expression, fibronectin and type IV collagen | Sirtuin-1, NF-κB                                                       | [141]     |
| *Allium sativum* (garlic)        | T1DM: STZ-induced diabetic rat                    | Increase sirtuin-1 and sirtuin-2 gene expression in kidney                                  | Sirtuin-1; sirtuin-2                                                   | [21]      |
| Glycyrrhizic acid                | T2DM: db/db mouse                                 | Anti-oxidant, anti-fibrotic                                                                  | AMPK/sirtuin-1/PGC-1α signaling                                        | [22]      |
| Grape seed proanthocyanidin extracts | T2DM: high-carbohydrate/high-fat diet and STZ-induced diabetic rat | Restore mitochondrial function, anti-apoptotic, anti-oxidant, increase nephrin and podocalyxin | AMPK/sirtuin-1/PGC-1α                                                  | [59]      |
| Hesperidin and quercetin         | T1DM: STZ-induced diabetic rat                    | Anti-oxidant                                                                                 | AMPK/sirtuin-1/PGC-1α signaling                                        | [142]     |
| INT-777 (G protein–coupled bile acid receptor TGR5 agonist) | T2DM: db/db mouse                               | Increase renal mitochondrial biogenesis, decrease oxidative stress, increase fatty acid beta-oxidation | Sirtuin-1, sirtuin-3, Nrf1, SOD2                                        | [143]     |
| Olmesartan                       | T2DM: db/db mice                                  | Anti-apoptotic, suppress p38 phosphorylation                                                | Angiotensin II/p38/sirtuin-1                                           | [118]     |
| Puerarin (active compound of Radix Puerariae) | STZ-induced diabetes in endothelial nitric oxide synthase–null (eNOS−/−) mouse | Anti-oxidant                                                                                 | NF-κB, NOX4                                                            | [81]      |
| *Panax notoginseng* saponins     | T1DM: STZ-induced diabetic mouse                  | Anti-oxidant, anti-inflammatory                                                               | Sirtuin-1/FOXO1, TNF-α, NF-κB, IL-6                                    | [87]      |
| Resveratrol                      | T1DM: STZ-induced diabetic rat                    | Anti-oxidant, prevent dephosphorylation of histone H3, reduce the expression of p38 and p53 | Sirtuin, p53, p38                                                      | [88]      |
|                                | T1DM: STZ-induced diabetic rat                    | Anti-oxidant                                                                                 | Sirtuin-1/FOXO1                                                        | [89]      |
|                                | T1DM: STZ-induced diabetic rat                    | Module angiogenesis                                                                           | Sirtuin-1, VEGF, Flk-1, Tie-2                                          | [115]     |
|                                | T1DM: STZ-induced diabetic rat                    | Anti-oxidant, anti-fibrotic                                                                   | Sirtuin-1, Nrf2/ARE, TGF-β1, FN                                       | [34]      |
|                                | T2DM: db/db mouse                                 | Prevent renal lipotoxicity and glucotoxicity, anti-oxidant, anti-apoptotic                    | AMPK/sirtuin-1/PGC-1α                                                 | [56]      |
|                                | T2DM: STZ-induced diabetic rat                    | Anti-inflammatory; enhance autophagy                                                          | NAD+ /sirtuin-1, TNF-α, IL-6, IL-1β, IL-10                             | [7]       |
|                                | T2DM: STZ-induced diabetic rat                    | Anti-oxidant                                                                                 | Sirtuin-1/FoxO3a                                                       | [89]      |
|                                | T2DM: STZ + niacinamide–induced diabetic rat      | Anti-oxidant, anti-fibrotic                                                                   | TGF-β1, NF-κBp65, Nrf2, sirtuin-1, FoxO1                               | [144]     |
| Roflumilast                      | T1DM: STZ-induced diabetic rat                    | Anti-oxidant, anti-fibrotic, anti-apoptotic                                                  | AMPK/sirtuin-1, FoxO1, HO-1                                             | [52]      |
| Theobromine                      | Spontaneously hypertensive rat treated with STZ    | Anti-fibrotic                                                                                | NOX4, AMPK, sirtuin-1/TGF-β                                           | [139]     |
| Tetrahydroxystilbene glucoside   | T1DM: STZ-induced diabetic rat                    | Anti-oxidant                                                                                 | Sirtuin-1/TGF-β1, COX-2                                               | [140]     |

*References for specific mechanisms and pathways:* [141], [21], [22], [59], [142], [143], [118], [81], [87], [88], [89], [56], [7], [144].
So far, sirtuin-1 activators, such as resveratrol, have not been shown definitively to have beneficial effects on DN in clinical trials, although they have been shown to have renoprotective effects in preclinical studies. DN takes several weeks to develop in animal models but many years to develop in humans; thus, the processes involved in the development of DN in human are probably more complicated than those in animal models. This might explain, at least partially, the differences in the effects of sirtuin-1 activators between clinical and preclinical studies. In addition, DN is generally progressive and irreversible at the time it is diagnosed. Therefore, when treatment is initiated will have a profound effect on the therapeutic outcomes of sirtuin-1 activator treatments in DN patients.

Conclusions and perspectives

Metabolic disturbance, OS, inflammation, impairs autophagy, hypoxia, abnormal angiogenesis, apoptosis, and activation of the RAS result in kidney lesions in diabetes. The deacetylase sirtuin-1 is involved in all of these aspects of the pathogenesis of DN. Downregulation of sirtuin-1 in diabetes increases the acetylation of histones and that of crucial transcription factors, including p53, FoxO, NF-κB, and Nrf2, which are involved in numerous feedback loops and networks that promote the development of DN. Its key role in DN makes sirtuin-1 a target for preventive and therapeutic purposes. Here, we summarized the synthetic drugs and natural compounds that are used in the treatment of DN and which target sirtuin-1. In vitro studies have identified the molecular effects of these substances in various types of renal cells, and preclinical studies have shown protective effects against DN and on sirtuin-1 and its downstream target proteins. Although some clinical trials demonstrated that sirtuin-1 activators, such as resveratrol, benefit patients with T2DM and microalbuminuria, others did not show protective effects, possibly due to differences in dose, disease stage, treatment duration, and the characteristics of the patients studied. Because the regulation and effects of sirtuin-1 are complex, further investigation of its molecular interactions, such as with miRNAs and lncRNAs, which may underpin its protective effects, is required. In addition, well-designed clinical trials in patients with T2DM and T1DM are required to assess the renoprotective effects of substances that have been shown to have beneficial effects exerted via sirtuin-1 in vitro and in vivo.

Authors’ contributions All authors wrote, revised, and approved the manuscript. All authors read and approved the final manuscript.

Funding information The authors’ work cited in this review was supported in part by grants from the National Natural Science Foundation of China (81400725 to W.S., 81700635 to Y.C.), the National Science Foundation of Jilin Province (20160101030JC to W.S.), the 13th Five-Year scientific research planning program of Jilin province (JJKH20180210KJ to W.S), the National Postdoctoral Program for Innovative Talents (BX201700098 to Y.C.), and the Postdoctoral Science Foundation of China (2017M621216 to Y.C.).

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Consent for publication Not applicable.

Ethics approval and consent to participate Not applicable.

Abbreviations ACE2, angiotensin-converting enzyme 2; AdipoR, adiponectin receptor; AGE, advanced glycation end product; AMPK, AMP-dependent protein kinase; Ang II, angiotensin II; ARE, anti-oxidant response element; Atg, autophagy-related gene; Bnip3, Bcl2/adenovirusE1V 19 kDa interacting protein 3; CAT, catalase; CDK5, cyclin-dependent kinase 5; CR, calorie restriction; CTGF, connective tissue growth factor; DN, diabetic nephropathy; ECM, extracellular matrix; EC, endothelial cell; EMT, epithelial-to-mesenchymal transition; FN, fibronectin; FOXO, forkhead box group O; GFR, glomerular filtration rate; GMC, glomerular mesangial cell; HG, high glucose; HIF-1α, hypoxia-inducible factor-1α; hnRNP F, heterogeneous nuclear ribonucleoprotein F; HO-1, heme oxygenase 1; ICAM-1, intercellular adhesion molecule-1; IF, insulin resistance; Keap1, Kelch-like ECH-associated protein 1; LC3, light chain 3; LincRNA, long intergenic non-coding RNA; LKB1, liver kinase B1; IncRNA, long non-coding RNA; MCP-1, monocyte chemotactic protein-1; miRNA, microRNA; Mn-SOD, manganese superoxide dismutase; NAD+, nicotinamide adenine dinucleotide; Nammpt, nicotinamide phosphoribosyltransferase; NF-κB, nuclear factor-κB; NMM, nicotinamide mononucleotide; NOX4, NADPH oxidase-4; NQO-1, NAD(P)H quinone dehydrogenase 1; Nrf2, nuclear factor erythroid 2-related factor 2; PAI-1, plasminogen activator inhibitor-1; p66Shc, 66 kDa Src homology 2 domain-containing protein; PG1-IX, peroxisome proliferator–activated receptor-γ coactivator 1α; PKC, protein kinase C; PPAR, peroxisome proliferator–activated receptor; PTC, proximal tubular cell; RAS, renin-angiotensin system; ROS, reactive oxygen species; Smad, small mothers against decapentaplegic homolog; SNPs, single nucleotide polymorphism; SOD, superoxide dismutase; STAT3, signal transducer and activator of transcription 3; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TNF-α, tumor necrosis factor-α; TGF-β1, transforming growth factor-β1; USP22, ubiquitin-specific protease 22; VACM-1, vascular cell adhesion protein-1; VEGF, vascular endothelial growth factor

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Gheith O, Farouk N, Nampoori N, Halim MA, al-Otaibi T (2016) Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol 5(1):49–56
2. Sadoul K, Boyault C, Pabion M, Khochbin S (2008) Regulation of protein turnover by acetyltransferases and deacetylases. Biochimie 90(2):306–312
3. Kong L et al (2015) Sirtuin 1: a target for kidney diseases. Mol Med 21:87–97
4. Michishita E, Park JY, Burnsiek JS, Barrett JC, Horikawa I (2005) Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell 16(10):4623–4635
5. Kitada M, Koya D (2013) SIRT1 in type 2 diabetes: mechanisms and therapeutic potential. Diabetes Metab J 37(5):315–325
6. Wakino S, Hasegawa K, Itoh H (2015) Sirtuin and metabolic kidney disease. Kidney Int 88(4):691–698
7. Ma L, Fu R, Duan Z, Lu J, Gao J, Tian L, Lv Z, Chen Z, Han J, Jia L, Wang L (2016) Sirt1 is essential for resveratrol enhancement of hypoxia-induced autophagy in the type 2 diabetic nephropathy rat. Pathol Res Pract 212(4):310–318
8. Zhao Y, Wei J, Hou X, Liu H, Guo F, Zhou Y, Zhang Y, Qu Y, Gu J, Zhou H, Jia X, Qin G, Feng L (2017) SIRT1 rs10823108 and FOXO1 rs17446614 responsible for genetic susceptibility to diabetic nephropathy. Sci Rep 7(1):10285
9. Pugliese G (2014) Updating the natural history of diabetic nephropathy. Acta Diabetol 51(6):905–915
10. Alberti KG, Zimmer PZ (1998) Definition, diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15(7):539–553
11. Tervaert TW et al (2010) Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 21(4):556–563
12. Wada J, Makino H (2013) Inflammation and the pathogenesis of diabetic nephropathy. Clin Sci (Lond) 124(3):139–152
13. Sifuentes-Franco S et al (2018) Oxidative stress, apoptosis, and mitochondrial function in diabetic nephropathy. Int J Endocrinol 2018:1875870
14. Takayama Y, Haneda M (2014) Hypoxia in diabetic kidneys. Biomed Res Int 2014:837421
15. Nakagawa T, Kosugi T, Haneda M, Rivard CJ, Long DA (2009) Abnormal angiogenesis in diabetic nephropathy. Diabetes 58(7):1471–1478
16. Tanabe K et al (2017) Antiangiogenic therapy for diabetic nephropathy. Biomed Res Int 2017:5724069
17. Maeda S, Koya D, Araki SI, Babazono T, Umezono T, Toyoda M, Kawai K, Imanami M, Uzu T, Suzuki D, Maegawa H, Kashiwagi A, Iwamoto Y, Nakamura Y (2011) Association between single nucleotide polymorphisms within genes encoding sirtuin families and diabetic nephropathy in Japanese subjects with type 2 diabetes. Clin Exp Nephrol 15(3):381–390
18. Tang K, Sun M, Shen J, Zhou B (2017) Transcriptional coactivator p300 and silent information regulator 1 (SIRT1) gene polymorphism associated with diabetic kidney disease in a Chinese cohort. Exp Clin Endocrinol Diabetes 125(8):530–537
19. Shao Y, Ren H, Lv C, Ma X, Wu C, Wang Q (2017) Changes of serum Mir-217 and the correlation with the severity in type 2 diabetes patients with different stages of diabetic kidney disease. Endocrine 55(1):130–138
20. Tikoo K, Tripathi DN, Kabra DG, Sharma V, Gaikwad AB (2007) Intermittent fasting prevents the progression of type 1 diabetic nephropathy in rats and changes the expression of Sir2 and p53. FEBS Lett 581(5):1071–1078
21. Arab Sadeghabadi Z, Ziamajidi N, Abbassalipourkabir R, Mohseni R (2018) Garlic (Allium sativum) increases SIRT1 and SIRT2 gene expressions in the kidney and liver tissues of STZ- and STZ+ niacinamide-induced diabetic rats. J Basic Clin Physiol Pharmacol 29:463–467
22. Hou S et al (2017) Glycyrrhizin acid prevents diabetic nephropathy by activating AMPK/SIRT1/PGC-1alpha signaling in db/db mice. J Diabetes Res 2017:2865912
23. Chen W, Chang B, Zhang Y, Yang P, Liu L (2015) Rhein promotes the expression of SIRT1 in kidney tissues of type 2 diabetic rat. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 31(5):615–619
24. Chuang PY, Xu J, Dai Y, Jia F, Mallipatlu SK, Yacoub R, Gu L, Premrutsirat PK, He JC (2014) In vivo RNA interference models of inducible and reversible Sir1 knockdown in kidney cells. Am J Pathol 184(7):1940–1956
25. Hasegawa K, Wakino S, Simie P, Sakamaki Y, Minakuchi H, Fujimura K, Hosoya K, Komatsu M, Kaneko Y, Kanda T, Kubota E, Tokuyama H, Hayashi K, Kuarente L, Itoh H (2013) Renal tubular Sirt1 attenuates diabetic albuminuria by epigenetically suppressing Claudin-1 overexpression in podocytes. Nat Med 19(11):1496–1504
26. Liu R, Zhong Y, Li X, Chen H, Jim B, Zhou MM, Chuang PY, He JC (2014) Role of transcription factor acetylation in diabetic kidney disease. Diabetes 63(7):2440–2453
27. Motonishi S, Nangaku M, Wada T, Ishimoto Y, Ohse T, Matsuura S, Kubota N, Shimizu A, Kadowaki T, Tobe K, Inagi R (2015) Sirtuin1 maintains actin cytoskeleton by deacetylation of cortactin in injured podocytes. J Am Soc Nephrol 26(8):1939–1959
28. Nakatani Y, Inagi R (2016) Epigenetic regulation through SIRT1 in podocytes. Curr Hypertens Rev 12(2):89–94
29. Chuang PY, Dai Y, Liu R, He H, Kretzler M, Jim B, Cohen CD, He JC (2011) Alteration of forkhead box O (foxo) acetylation mediates apoptosis of podocytes in diabetes mellitus. PLoS One 6(8):e22566
30. Hasegawa K, Wakino S, Sakamaki Y, Muraoka H, Umino H, Minakuchi H, Yoshifuji A, Naitoh M, Shinouzuka K, Futatsugi K, Urai H, Kanda T, Tokuyama H, Hayashi K, Itoh H (2016) Communication from tubular epithelial cells to podocytes through Sirt1 and nicotinic acid metabolism. Curr Hypertens Rev 12(2):95–104
31. Gong Y, Sunq A, Roth RA, Hou J (2017) Inducible expression of claudin-1 in glomerular podocytes generates aberrant tight junctions and proteinuria through slit diaphragm destabilization. J Am Soc Nephrol 28(1):106–117
32. Shao Y, Lv C, Wu C, Zhou Y, Wang Q (2016) Mir-217 promotes inflammation and fibrosis in high glucose cultured rat glomerular mesangial cells via Sirt1/HIF-1alpha signaling pathway. Diabetes Metab Res Rev 32(6):534–543
33. Zhou L, Fu B, Bai X, Zhang B, Wu L, Cui J, Cui S, Wei R, Chen X, Cai G (2011) NAD blocks high glucose induced mesangial hypertrophy via activation of the sirtuins-AMPK-mTOR pathway. Cell Physiol Biochem 27(6):681–690
34. Huang K, Huang J, Xie X, Wang S, Chen C, Shen X, Liu P, Huang H (2013) Sirt1 resists advanced glycation end products-induced expressions of fibronectin and TGF-beta1 by activating the Nr2f2/ARE pathway in glomerular mesangial cells. Free Radic Biol Med 55:528–540
35. Chen Y, Liang Y, Hu T, Wei R, Cai C, Wang P, Wang L, Qiao W, Feng L (2017) Endogenous Nampt upregulation is associated with diabetic nephropathy inflammatory-fibrosis through the NF-kappaB p65 and Sirt1 pathway; NMN alleviates diabetic nephropathy inflammatory-fibrosis by inhibiting endogenous Nampt. Exp Ther Med 14(5):4181–4193
36. Kida Y, Zullo JA, Goligorsky MS (2016) Endothelial sirtuin 1 inactivation enhances capillary rarefaction and fibrosis following kidney injury through Notch activation. Biochem Biophys Res Commun 478(3):1074–1079
37. Chen J, Xavier S, Moskowitz-Kassai E, Chen R, Lu CY, Sanduski K, Špes A, Turk B, Goligorsky MS (2012) Cathepsin cleavage of...
72. Zhou S, Chen HZ, Yan YZ, Zhang QJ, Wei YS, Huang S, Liu JJ, Lu YB, Zhang ZQ, Yang RF, Zhang R, Cai H, Liu DP, Liang CC (2011) Repression of p66Shc expression by SIRT1 contributes to the prevention of hyperglycemia-induced endothelial dysfunction. Circ Res 109(6):639–648
73. Song P et al (2014) PKCdelt alpha promotes high glucose induced renal tubular oxidative damage via regulating activation and translocation of p66Shc. Oxidative Med Cell Longev 2014:746531
74. Sun L, Xiao L, Nie J, Liu FY, Ling GH, Zhu XJ, Yuan X, Chen WC, Xia YC, Zhan M, Ma MM, Peng YM, Liu H, Liu YH, Kanwar YS (2010) p66Shc mediates high-glucose and angiotensin II-induced oxidative stress renal tubular injury via mitochondrial-dependent apoptotic pathway. Am J Physiol Ren Physiol 299(5):F1014–F1025
75. Li Q, Kim YR, Vikram S, Kassan M, Gabani M, Lee SK, Jacobs JS, Irani K (2016) P66Shc-induced MicroRNA-34a causes diabetic endothelial dysfunction by downregulating sirtuin1. Arterioscler Thromb Vasc Biol 36(12):2394–2403
76. Higgins DF, Kimura K, Bernhardt WM, Shimanker N, Akai Y, Hohenstein B, Saito Y, Johnson RS, Kretzler M, Cohen CD, Eckardt KU, Iwano M, Haase VH (2007) Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 117(12):3810–3820
77. Gasparini C, Feldmann M (2012) NF-kappaB as a target for modulating inflammatory responses. Curr Pharm Des 18(35):5735–5745
78. Du YG et al (2018) Tangsheen formula improves inflammation in renal tissue of diabetic nephropathy through SIRT1/NF-kappaB pathway. Exp Ther Med 15(2):2156–2164
79. Guo R, Liu B, Wang K, Zhou S, Li W, Xu Y (2014) Resveratrol ameliorates diabetic vascular inflammation and macrophage infiltration in db/db mice by inhibiting the NF-kappaB pathway. Diab Vasc Dis Res 11(2):92–102
80. Du YG et al (2016) Panax notoginseng saponins protect kidney from diabetes by up-regulating silent information regulator 1 and activating antioxidant proteins in rats. Chin J Integr Med 22(12):910–917
81. Li X, Cai W, Lee K, Liu B, Deng Y, Chen Y, Zhang X, He JC, Zhong Y (2017) Puerarin attenuates diabetic kidney injury through the suppression of NOX4 expression in podocytes. Sci Rep 7(1):14603
82. van der Vos KE, Coffer PJ (2011) The extending network of FOXO transcriptional target genes. Antioxid Redox Signal 14(4):379–392
83. Lalmansingh AS, Karmakar S, Jin Y, Nagaich AK (2012) Multiple modes of chromatin remodeling by Forkhead box proteins. Biochim Biophys Acta 1819(7):707–715
84. Murtaza G et al (2017) FOXO transcriptional factors promote autophagy in cardiomyocytes. J Biol Chem 292(41):28319–28331
85. Hariharan N, Maejima Y, Nakae J, Paik J, DePinho RA, Sadoshima J (2010) Deacetylation of FOXO by Sirt1 plays an essential role in mediating starvation-induced autophagy in cardiomyocytes. Circ Res 107(12):1470–1482
86. Wu L, Zhang Y, Ma X, Zhang N, Qin G (2012) The effect of resveratrol on FoxO1 expression in kidneys of diabetic nephropathy rats. Mol Biol Rep 39(9):9085–9093
87. Wang X, Meng L, Zhao L, Wang Z, Liu H, Liu G, Guan G (2017) Resveratrol ameliorates hyperglycemia-induced renal tubular oxidative stress damage via modulating the SIRT1/FOXO3a pathway. Diabetes Res Clin Pract 126:172–181
88. Sengupta A, Mokkentin JD, Yutzeey KE (2009) FoxO transcription factors promote autophagy in cardiomyocytes. J Biol Chem 284(1):28319–28331
89. Agostino M, Beji S, Torcinaro A, Rizzi R, Zaccagnini G, Maimone B, di Stefano V, de Santa F, Cordisco Hohenstein B, Saito Y, Johnson RS, Kretzler M, Cohen CD, Eckardt KU, Iwano M, Haase VH (2007) Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 117(12):3810–3820
90. Kume S, Uzu T, Horiike K, Chin-Kanaski M, Ishikii K, Araki SI, Sugimoto T, Haneda M, Kashigawa A, Koya D (2010) Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. J Clin Invest 120(4):1043–1055
91. Ong ALC, Ramasamy TS (2018) Role of sirtuin1-p53 regulatory axis in aging, cancer and cellular reprogramming. Ageing Res Rev 43:64–80
92. Wang XL, Wu LY, Zhao L, Sun LN, Liu HY, Liu G, Guan GJ (2016) SIRT1 activator ameliorates the renal tubular injury induced by hyperglycemia in vivo and in vitro by inhibiting apoptosis. Biomed Pharmacother 83:41–50
93. Tikoo K, Singh K, Kabra D, Sharma V, Gaikwad A (2008) Change in histone H3 phosphorylation, MAP kinase p38, SIRT 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radic Res 42(4):397–404
94. Wang Y, Zheng ZJ, Jia YJ, Yang YL, Xue YM (2018) Role of p53/ miR-155-5p/sirt1 loop in renal tubular injury of diabetic kidney disease. J Transl Med 16(1):146
95. Yu L, Chen Y, Tooze SA (2018) Autophagy pathway: cellular and molecular mechanisms. Autophagy 14(2):207–215
96. Huang R, Xu Y, Wan W, Shou X, Qian J, You Z, Liu B, Chang C, Zhou T, Lippincott-Schwartz J, Liu W (2015) Deacetylation of nuclear LC3 drives autophagy initiation under starvation. Mol Cell 57(3):456–466
97. Tanaka Y et al (2012) Autophagy as a therapeutic target in diabetic nephropathy. Exp Diabetes Res 2012:628978
98. Kume S, Yamahara K, Yasuda M, Maegawa H, Koya D (2014) Autophagy: emerging therapeutic target for diabetic nephropathy. Semin Nephrol 34(1):9–16
99. Kume S, Koya D (2015) Autophagy: a novel therapeutic target for diabetic nephropathy. Diabetes Metab J 39(6):451
100. Kitada M, Ogura Y, Monno I, Koya D (2017) Regulating autophagy as a therapeutic target for diabetic nephropathy. Curr Pharm Des 23(35):5735–5745
101. Wang Y, Zheng ZJ, Jia YJ, Yang YL, Xue YM (2018) Role of p53/ miR-155-5p/sirt1 loop in renal tubular injury of diabetic kidney disease. J Transl Med 16(1):146
102. Wang Y, Zheng ZJ, Jia YJ, Yang YL, Xue YM (2018) Role of p53/ miR-155-5p/sirt1 loop in renal tubular injury of diabetic kidney disease. J Transl Med 16(1):146
103. Yu L, Chen Y, Tooze SA (2018) Autophagy pathway: cellular and molecular mechanisms. Autophagy 14(2):207–215
104. Huang R, Xu Y, Wan W, Shou X, Qian J, You Z, Liu B, Chang C, Zhou T, Lippincott-Schwartz J, Liu W (2015) Deacetylation of nuclear LC3 drives autophagy initiation under starvation. Mol Cell 57(3):456–466
105. Tanaka Y et al (2012) Autophagy as a therapeutic target in diabetic nephropathy. Exp Diabetes Res 2012:628978
106. Kume S, Yamahara K, Yasuda M, Maegawa H, Koya D (2014) Autophagy: emerging therapeutic target for diabetic nephropathy. Semin Nephrol 34(1):9–16
107. Kume S, Koya D (2015) Autophagy: a novel therapeutic target for diabetic nephropathy. Diabetes Metab J 39(6):451–460
108. Kitada M, Ogura Y, Monno I, Koya D (2017) Regulating autophagy as a therapeutic target for diabetic nephropathy. Curr Diab Rep 17(7):53
109. Lee IH, Cao L, Mostoslavsky R, Lombard DB, Liu J, Bruns NE, Tsokos M, Alt FW, Finkel T (2008) A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci U S A 105(9):3374–3379
110. Su Y, Lu J, Gong P, Chen X, Liang C, Zhang J (2018) Rapamycin induces autophagy to alleviate acute kidney injury following cerebro ischemia and reperfusion via the mTORC1/AGT313ULK1 signaling pathway. Mol Med Rep 8:5445–5454
111. Ding Y, Choi ME (2015) Autophagy in diabetic nephropathy. J Endocrinol 224(1):R15–R30
112. Tang F, Hao Y, Zhang X, Qin J (2017) Effect of echinacoside on kidney fibrosis by inhibition of TGF-beta1/Smads signaling pathway in the db/db mouse model of diabetic nephropathy. Drug Des Devel Ther 11:2813–2826
113. Yao Y, Li Y, Zeng X, Ye Z, Li X, Zhang L (2018) Losartan alleviates renal fibrosis and inhibits endothelial-to-mesenchymal transition (EMT) under high-fat diet-induced hyperglycemia. Front Pharmacol 9:1213
108. Zhang Y, Connelly KA, Thai K, Wu X, Kapus A, Kepcets D, Gilbert RE (2017) Sirtuin 1 activation reduces transforming growth factor-beta1-induced fibrogenesis and affords organ protection in a model of progressive, experimental kidney and associated cardiac disease. Am J Pathol 187(1):80–90

109. Bugeyei-Twum A, Ford C, Civitarese R, Seegobin J, Advani SL, Desjardins JF, Kabir G, Zhang Y, Mitchell M, Switzer J, Thai K, Shen V, Abadeh A, Singh KK, Billia F, Advani A, Gilbert RE, Connelly KA (2018) Sirtuin 1 activation attenuates cardiac fibrosis in a rodent pressure overload model by modifying Smad2/3 transactivation. Cardiovasc Res 114(12):1629–1641

110. Li J, Xu Q, Ricardo SD, Bertram JM, Nikolic-Paterson DJ (2010) Resveratrol inhibits renal fibrosis in the obstructed kidney: potential role in deacetylation of Smad3. Am J Pathol 177(3):1065–1071

111. Mortuza R, Feng B, Chakraborti S (2015) SIRT1 reduction causes renal and retinal injury in diabetes through endothelin 1 and transforming growth factor beta1. J Cell Mol Med 19(8):1857–1867

112. Kanesaki Y, Suzuki D, Uehara G, Toyoda M, Katoh T, Sakai H, Watanabe T (2005) Vascular endothelial cell growth factor gene expression and association with endothelial cell proliferation. J Biol Chem 280(12):6729–6733

113. Guo D, Jia Q, Song HY, Warren RS, Donner DB (1995) Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. J Biol Chem 270(12):6729–6733

114. Davis B, Dei Cas A, Long DA, White KE, Hayward A, Ku CH, Woolf AS, Bilous JD, Vignali L, Gruen D (2007) Podocyte-specific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia. Am J Pathol 168(4):2320–2329

115. Wen D, Huang X, Zhang M, Zhang L, Chen J, Gu Y, Hao CM (2013) Resveratrol attenuates diabetic nephropathy via modulating angiogenesis. PLoS One 8(12):e82336

116. Mori J, Patel VB, Ramprashad T, Alrob OA, Desaulniers J, Scholey JW, Lopaschuk GD, Oudit GY (2014) Angiotensin 1-7 mediates renoprotection against diabetic nephropathy by reducing oxidative stress, inflammation, and lipotoxicity. Am J Physiol Renal Physiol 306(8):F812–F821

117. Clarke NE, Belyaev ND, Lambert DW, Turner AJ (2014) Epigenetic regulation of angiotensin-converting enzyme 2 (ACE2) by SIRT1 under conditions of cell energy stress. Clin Sci (Lond) 126(7):507–516

118. Gu J, Yang M, Qi N, Mei S, Chen J, Song S, Jing Y, Chen M, He L, Sun L, Hu H, Li L, Wu XR, Wu M, Mei C (2016) Olmesartan prevents microalbuminuria in db/db diabetic mice through inhibition of angiotensin II/p38/SIRT1-induced podocyte apoptosis. Kidney Blood Press Res 41(6):848–864

119. Benito-Martín A, Uceró AC, Izquierdo MC, Santamaría B, Picatoste B, Carrasco S, Lorenzo O, Ruiz-Ortega M, Egidio J, Ortiz A (2014) Endogenous NAMPT dampens chemokine expression and apoptotic responses in stressed tubular cells. Biochim Biophys Acta 1842(2):293–303

120. Lo CS, Shi Y, Chenier I, Ghosh A, Wu CH, Caihier JF, Ethier J, Lattouf JB, Filep JG, Ingelfinger JR, Zhang SL, Chan JSD (2017) Heterogeneous nuclear ribonucleoprotein F stimulates sirtuin-1 gene expression and attenuates nephropathy progression in diabetic mice. Diabetes 66(7):1964–1978

121. Li A, Peng R, Sun Y, Liu H, Peng H, Zhang Z (2018) LinRNA 1700002014Rik alleviates cell proliferation and fibrosis in diabetic nephropathy via miR-34a-5p/Sirt1/HIF-1alpha signaling. Cell Death Dis 9(5):461

122. El-Samahy MH et al (2018) Urinary miRNA-377 and miRNA-216a as biomarkers of nephropathy and subclinical atherosclerotic risk in pediatric patients with type 1 diabetes. J Diabetes Complicat 32(2):185–192

123. Duan LJ, Ding M, Hou LJ, Cui YT, Li CJ, Yu DM (2017) Long noncoding RNA TUG1 alleviates extracellular matrix accumulation via mediating microRNA-377 targeting of PPARgamma in diabetic nephropathy. Biochem Biophys Res Commun 484(3):598–604

124. Peng J et al (2017) MiR-377 promotes white adipose tissue inflammation and decreases insulin sensitivity in obesity via suppression of sirtuin-1 (SIRT1). Oncotarget 8(41):70550–70563

125. Baker MA, Davis SJ, Liu P, Pan X, Williams AM, Iczkowski KA, Gallagher ST, Bishop K, Regner KR, Liu Y, Liang M (2017) Tissue-specific microRNA expression patterns in four types of kidney disease. J Am Soc Nephrol 28(10):2985–2992

126. Huang KP, Chen C, Hao J, Huang JY, Liu PQ, Huang HQ (2015) AGIes-RAGE system down-regulates Sirt1 through the ubiquitin-proteasome pathway to promote FN and TGF-beta1 expression in male rat glomerular mesangial cells. Endocrinology 156(1):268–279

127. Yin Y, Li X, Sha X, Xi H, Li YF, Shao Y, Mai J, Virtue A, Lopez-Pastrana J, Meng S, Tilley DG, Monroy MA, Choi ET, Thomas CJ, Jiang X, Wang H, Yang XF (2015) Early hyperlipidemia promotes endothelial activation via a caspase-1-sirtuin 1 pathway. Arterioscler Thromb Vasc Biol 35(4):804–816

128. Shahzad K, Bock F, al-Dabet MM, Gadi I, Kohli S, Nazir S, Ghosh S, Ranjan S, Wang H, Madhusudhan T, Nawroth PP, Isermann B (2016) Caspase-1, but not caspase-3, promotes diabetic nephropathy. Am J Clin Pathol 278(8):2270–2275

129. Huang CY, Kuo WW, Yeh YL, Ho TJ, Lin JY, Lin DY, Chu CH, Tsai FJ, Tsai CH, Huang CY (2014) ANG II promotes IGF-IR expression and cardiomyocyte apoptosis by inhibiting HSF1 via JNK activation and SIRT1 degradation. Cell Death Differ 21(8):1262–1274

130. Bai B, Liang Y, Xu C, Lee MYK, Xu A, Wu D, Vanhoutte PM, Wang Y (2012) Cyclin-dependent kinase 5-mediated hyperphosphorylation of sirtuin-1 contributes to the development of endothelial senescence and atherosclerosis. Circulation 126(6):729–740

131. Zhang Q, Zhang P, Qi GJ, Zhang Z, He F, Lv ZX, Peng X, Cai HW, Li TX, Wang XM, Tian B (2018) Cdk5 suppression blocks SIRT1 degradation via the ubiquitin-proteasome pathway in Parkinson’s disease models. Biochim Biophys Acta Gen Subj 1862(6):1443–1451

132. Zhang Y, Gao X, Chen S, Zhao M, Chen J, Liu R, Cheng S, Qi M, Wang S, Liu W (2017) Cyclin-dependent kinase 5 contributes to endoplasmic reticulum stress induced podocyte apoptosis via promoting MEKK1 phosphorylation at Ser280 in diabetic nephropathy. Cell Signal 31:31–40

133. Bai X et al (2016) Cdk5 promotes renal tubulointerstitial fibrosis in diabetic nephropathy via ERK1/2/PPARgamma pathway. Oncotarget 7(24):36510–36528

134. Shi JX, Huang Q (2018) Glucagon-like peptide-1 protects mouse podocytes against high glucose-induced apoptosis, and suppresses reactive oxygen species production and proinflammatory cytokine secretion, through sirtuin 1 activation in vitro. Mol Med Rep 18(2):1789–1797

135. Bao L, Cai X, Zhang Z, Li Y (2015) Grape seed procyanidin B2 stimulates sirtuin-1 expression and attenuates nephropathy progression in diabetic nephropathy via ERK1/2/PPARgamma pathway. J Diabetes Complicat 32(2):185–192.
effects on SIRT1 and AMPK. Biochim Biophys Acta 1864(1): 115–125
137. Yang S, Zhao L, Han Y, Liu Y, Chen C, Zhan M, Xiong X, Zhu X, Xiao L, Hu C, Liu F, Zhou Z, Kanwar YS, Sun L (2017) Probenecid ameliorates renal injury in diabetic nephropathy by inhibiting the expression of the redox enzyme p66Shc. Redox Biol 13:482–497
138. Yang J, Wang N, Zhu Y, Feng P (2011) Roles of SIRT1 in high glucose-induced endothelial impairment: association with diabetic atherosclerosis. Arch Med Res 42(5):354–360
139. Papadimitriou A, Silva KC, Peixoto EBMI, Borges CM, Lopes de Faria JM, Lopes de Faria JB (2015) Theobromine increases NAD(+)Sirt-1 activity and protects the kidney under diabetic conditions. Am J Physiol Ren Physiol 308(3):F209–F225
140. Li C, Cai F, Yang Y, Zhao X, Wang C, Li J, Jia Y, Tang J, Liu Q (2010) Tetrahydroxystilbene glucoside ameliorates diabetic nephropathy in rats: involvement of SIRT1 and TGF-beta1 pathway. Eur J Pharmacol 649(1–3):382–389
141. Shang G, Gao P, Zhao Z, Chen Q, Jiang T, Zhang N, Li H (2013) 3,5-Diiodo-1-thyronine ameliorates diabetic nephropathy in streptozotocin-induced diabetic rats. Biochim Biophys Acta 1832(5):674–684
142. Iskender H, Dokumacioglu E, Sen TM, Incé I, Kanbay Y, Saral S (2017) The effect of hesperidin and quercetin on oxidative stress, NF-kappaB and SIRT1 levels in a STZ-induced experimental diabetes model. Biomed Pharmacother 90:500–508
143. Wang XX, Edelestein MH, Gafter U, Qiu L, Luo Y, Dobrinskikh E, Lucia S, Adorini L, DAgati VD, Levi J, Rosenberg A, Kopp JB, Gius DR, Saleem MA, Levi M (2016) G protein-coupled bile acid receptor TGR5 activation inhibits kidney disease in obesity and diabetes. J Am Soc Nephrol 27(5):1362–1378
144. Hussein MM, Mahfouz MK (2016) Effect of resveratrol and rosvuastatin on experimental diabetic nephropathy in rats. Biomed Pharmacother 82:685–692
145. Zhang J, Cheng Y, Gu J, Wang S, Zhou S, Wang Y, Tan Y, Feng W, Fu Y, Mellen N, Cheng R, Ma J, Zhang C, Li Z, Cai L (2016) Fenofibrate increases cardiac autophagy via FGF21/SIRT1 and prevents fibrosis and inflammation in the hearts of Type 1 diabetic mice. Clin Sci (Lond) 130(8):625–641
146. Cheng Y, Zhang J, Guo W, Li F, Sun W, Chen J, Zhang C, Lu X, Tan Y, Feng W, Fu Y, Liu GC, Xu Z, Cai L (2016) Up-regulation of Nrf2 is involved in FGF21-mediated fenofibrate protection against type 1 diabetic nephropathy. Free Radic Biol Med 93: 94–109
147. Ozturk E et al (2017) Resveratrol and diabetes: a critical review of clinical studies. Biomed Pharmacother 95:230–234
148. Bo S, Ponzo V, Ciccone G, Evangelista A, Saba F, Goitre I, Procopio M, Pagano GF, Cassader M, Gambino R (2016) Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. Pharmacol Res 111:896–905
149. Movahed A et al (2013) Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid Based Complement Alternat Med 2013:851267
150. Sattarinezhad A, Roozbeh J, Shirazi Yeganeh B, Omrani GR, Shams M (2019) Resveratrol reduces albuminuria in diabetic nephropathy: a randomized double-blind placebo-controlled clinical trial. Diabetes Metab 45(1):53–59
151. Kar P, Laitd D, Rooprai HK, Shaw KM, Cummings M (2009) Effects of grape seed extract in Type 2 diabetic subjects at high cardiovascular risk: a double blind randomized placebo controlled trial examining metabolic markers, vascular tone, inflammation, oxidative stress and insulin sensitivity. Diabet Med 26(5):526–531
152. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J, Mimran A, Rabelink TJ, Ritz E, Ruijlope LM, Rump LC, Viberi G, ROADMAP Trial Investigators (2011) Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 364(10):907–917